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Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq
Next-Generation Sequencing on Clinical Decision-Making
Tiroid Nodülü Genomik Profillemesi: ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme
Üzerinde Güncel Rolü
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1University
2Florida

of Miami Hospital, Clinic of Diabetes and Metabolism, Division of Endocrinology, Florida, USA
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Abstract
In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant
neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a
large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis
in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology.
Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role
in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies
assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules
with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there
are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decisionmaking in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results
of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines
regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.
Keywords: Thyroid cancer, thyroid nodule, genomic profiling, next-generation sequencing, ThyroSeq, molecular testing

Öz
Son yıllarda benign ve malign tiroid neoplazmlarının altında yatan genetik değişiklerle ilgili artan bir farkındalık oluşmuştur.
Yeni nesil dizinleme [Next-generation sequencing (NGS)] tiroid ince iğne aspirasyon (İİA) örneklerinde çok sayıda genetik
mutasyonun hızlı tespitine izin veren ve gelişmekte olan bir teknolojidir. Tiroid tümörlerinin hedeflenen mutasyon analizi
için NGS, İİA ile belirsiz sitoloji saptanan tiroid nodüllerinin tanısında yardımcı olmak için bir araç olarak öne sürülmüştür.
Ek olarak, tiroid nodülü ve tiroid kanserlerinin genomik test sonuçlarının prognostik etkileri olabilir ve hedefli tedaviler dahil
olmak üzere uygun tedavi stratejilerinin belirlenmesinde önemli bir rol oynayabilir. Bu yazıda İİA ile belirsiz sitolojisi olan tiroid
nodüllü hastaların tanı ve tedavisinde ThyroSeq NGS testinin performansını değerlendiren mevcut çalışmaların bir derlemesini
sunmayı ve bu çalışmalardan elde edilen bulguların klinik pratikte uygulanabilirliğini tartışmayı amaçladık. Her ne kadar erken
veriler NGS’den elde edilen verilerin tiroid kanserinde prognoz ve tedavi kararı sürecine olası yardımlarını öne sürse de, bu tür
moleküler testlerin devam eden klinik çalışmaların sonuçları belirlenene kadar, akıllıca kullanılmasını ve dikkatli yorumlanmasını
öneriyoruz. Son olarak, tiroid nodüllerinin tanısal değerlendirilmesinde NGS ile mutasyon tespiti ile ilgili klinik uygulama
kılavuzlarından edinilmiş öneriler tartışılmıştır.
Anahtar kelimeler: Tiroid kanseri, tiroid nodülü, genomik profilleme, yeni nesil dizinleme, ThyroSeq, moleküler test
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Introduction

a two-step procedure of thyroid lobectomy followed by
a completion thyroidectomy in the circumstance that the
lobectomy results in a diagnosis of thyroid cancer.
Taking into consideration that many thyroid cancers
are indolent tumors and that many patients may have
an excellent prognosis even when the diagnosis and
treatment has been delayed and the fact that most patients
who undergo thyroidectomy for AUS/FLUS and FN/SFN
cytopathology will be diagnosed with benign nodules on
final surgical histopathology, clinicians and patients have
been left with weighing the risks of a more conservative
strategy of surveillance with that of the more aggressive
approach of proceeding to thyroidectomy.
A variety of factors can predict the risk of cancer and aid in
the decision on optimal management for patients presenting
with nodules having indeterminate cytopathology; including
patient risk factors (age, gender, family history, past exposure
to ionizing radiation), serum TSH level and presence or
absence of sonographic features suspicious for papillary
thyroid cancer (PTC) (6,8,9). In their 2015 management
guidelines pertaining to adults with thyroid nodules, the
American Thyroid Association (ATA) has provided clear
guidance on the criteria that should be used to determine
the initial indication for FNA based on traditional risk factors
and in particular a risk stratification model heavily reliant
upon sonographic appearance of the nodule (6).
However, in the circumstance that FNA is performed,
once patients and health care providers are faced with
indeterminate cytology, it becomes much less clear from the
guidelines precisely how the same criteria should be used
to inform management decisions. This situation has created
a need to improve on the cytological inaccuracy inherent
to the diagnosis of indeterminate thyroid FNA, resulting in
the development of a number of new diagnostic modalities
intended for application as a “rule-in” or “rule-out” test for
thyroid cancer. When discussing the performance of any
of these tests it must be taken into consideration that the
ideal ‘rule-in’ test should have a positive predictive value
(PPV) similar to that of a malignant cytological diagnosis

Thyroid nodules are common in the general population
with higher prevalence in women and in older persons.
When ultrasound is performed at random in the general
population 19-68% of individuals are found to harbor one
or more thyroid nodules (1). While the majority of these
nodules are not clinically significant 7-15% are malignant
(2). Paralleling the increased use of imaging techniques
and of thyroid fine-needle aspiration (FNA) there has been
dramatic increase worldwide in both the incidence of
thyroid nodule diagnosis and that of thyroid cancer over
the past 20-30 years (3,4).
Several clinical practice guidelines have set forth strategies
to manage patients who are discovered to have thyroid
nodules, yet a great deal of controversy still exists as to
the optimal approach to diagnosis and treatment (5,6).
The widespread use of high-resolution ultrasonography of
the neck as well as thyroid FNA has significantly enhanced
our ability to diagnose malignancy among thyroid nodules,
however 20-30% of cytology results from thyroid FNA
fall into one of three indeterminate diagnostic categories
according to the Bethesda System for Reporting Thyroid
Cytopathology: Atypia of undetermined significance/
Follicular lesion of undetermined significance (AUS/FLUS)
(Bethesda category III), follicular neoplasm/suspicious for
follicular neoplasm (FN/SFN) (Bethesda category IV), and
Suspicious for malignancy (SM) (Bethesda category V) (7).
The reported frequency and risk of malignancy with each of
the Bethesda reporting categories is summarized in Table 1.
Patients and physicians faced with an indeterminate
cytopathology report will have to make the sometimes
difficult decision of deciding on the next step in
management of the thyroid nodule, which until recent
years has meant choosing from one of three options: repeat
FNA, observation with continued ultrasound surveillance or
surgical management. Each of these strategies brings with
it specific considerations and complexities; for instance
in patients referred for surgery the need to decide upon
the extent of thyroidectomy and the potential need for

Table 1. Bethesda system for the classification of thyroid cytopathology
Bethesda
category

Cytopathologic
category

Approximate
expected frequency

Malignancy rate

Suggested treatment (Prior to
availability of molecular testing)

I

Non-diagnostic/Inadequate

5-11%

1-4%

Repeat FNA

II

Benign

55-74%

0-3%

US follow-up

III

Atypia/follicular lesion of
undetermined significance

5-15%

5-15%

Repeat FNA or US follow-up or
Lobectomy

IV

Follicular neoplasm/
suspicious for FN

2-25%

15-30%

Lobectomy

V

Suspicious for malignancy

1-6%

60-75%

Lobectomy or Thyroidectomy

VI

Malignant

2-5%

97-99%

Near-total thyroidectomy

FNA: Fine-needle aspiration, FN: Follicular neoplasm, US: Ultrasonographic
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(Bethesda category VI) (98.6%), while an ideal ‘ruleout’ test should have a negative predictive value (NPV)
comparable to that of benign cytology (Bethesda category
II) (96.3%) (7).
In recent years a number of diagnostic tests have been
evaluated to aid in the diagnosis of indeterminate thyroid
nodules, including FDG-PET and several assessments of
molecular markers in FNA specimens (10,11). Molecular
tests include immunohistochemistry for Galectin -3, HBME1 and CK19; gene expression and microarray analysis;
microRNA expression; and testing for mutations and gene
rearrangements (6,12). Currently in the U.S.A. commercially
available molecular tests include those for single or multiple
mutation analysis, combination panels for mutation analysis
and chromosomal rearrangements (miRInform®-Asuragen,
ThyroSeq-CBLPath and University of Pittsburgh Medical
Center) and a proprietary gene expression classifier
(Afirma GEC®-Veracyte) (13,14,15). While initially the
gene expression classifier (GEC) was proposed as the best
among these tests to rule-out malignancy and mutation
analysis was preferred as a “rule-in”, the next-generation
sequencer (NGS) ThyroSeq has recently been shown to
have both a high PPV and NPV for thyroid cancer diagnosis
when applied to thyroid FNA with indeterminate cytology
(16,17,18). A further strength of the ThyroSeq, when
compared to GEC, is that it provides detailed and specific
information regarding the exact genetic alteration driving
the disease, which could potentially provide prognostic and
therapeutic implications including impacting upon extent of
surgery, use of RAI and possible future targeted therapies.
Thyroid cancer, like all cancers, is a disease of the genome.
The initiation and progression of cancer is due to the
accumulation of genetic and epigenetic changes such as
somatic mutations, chromosomal rearrangements, micro
RNA dysregulation and alterations in gene expression
(19). In differentiated thyroid cancer (DTC), the observed
genetic changes frequently lead to activation of the
MAPK or PI3K-AKT pathways. Approximately 70% of DTC
demonstrate one of four genetic abnormalities: point
mutations in the BRAF or RAS gene or either one of two
chromosomal rearrangements: RET/PTC or PAX8/PPARG
(19). Our knowledge of the genomic alterations explaining
the remaining approximately 30% of all thyroid cancers
not harboring one of the aforementioned four genetic
aberrations has been greatly expanded by a number of
recent discoveries, including those reported in 2014 by
the National Cancer Genome Atlas Research Network, in
which the genetic driver was identified in 96.5% of 496
PTC cases (20,21). The findings of this last report have led
some experts to propose a reclassification of PTCs based on
molecular characteristics to better reflect their underlying
differentiation and signaling properties (21). While a
detailed discussion of all current molecular tests in thyroid
FNA is beyond the scope of this article, our review will focus
on the role of NGS, a methodology which we believe may
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hold particular promise in diagnosis of thyroid FNA as well
as future potential for use in prognostication and informing
management of patients with thyroid cancer.

Next-generation Sequencing in Thyroid FineNeedle Aspiration
NGS is a method of simultaneous sequencing of a very
large number of short nucleic acid sequences that can be
used to detect multiple genetic alterations in large regions
of the genome (22). Compared to standard methods of
sequencing, such as Sanger sequencing, NGS has the
advantage of rapid simultaneous sequencing of large
sections of the genome and quantitative assessment
of mutated alleles. NGS can be used for whole-genome
sequencing as well as in a more targeted manner directed
at specific mutations in specific areas of the genome.
The ThyroSeq NGS panel provides simultaneous sequencing
for detection in over a thousand hotspots of 14 thyroid
cancer-related genes and for 42 types of gene fusions
occurring in thyroid cancer (14,17). The genes analyzed for
mutation are AKT1, BRAF, CTTNB1, GNAS, HRAS, KRAS,
NRAS, PIK3CA, PTEN, RET, TP53, TSHR, TERT and EIF1AX.
The gene list for gene fusions and expression consists of
RET, PPARG, NTRK1, NTRK3, ALK, IGF2BP3, BRAF, MET,
CALCA, PTH, SLC5A5, TG, TTF1, KRT7 and KRT20.
The proposed uses for NGS for thyroid FNA samples include
diagnosis of cytologically indeterminate thyroid nodules,
prognostication in thyroid cancer and to inform selection
of targeted therapies (14). The possible applications and
indications of ThyroSeq include:
1. Thyroid FNA with indeterminate cytology (Bethesda
categories III, IV and V),
2. Malignant thyroid cytology (Bethesda category VI),
when results of the NGS are expected to affect the decision
for extent of oncological surgery,
3. Benign thyroid cytology (Bethesda category II), when
strong SM exists on clinical grounds such as presence of a
highly suspicious sonographic pattern,
4. When the diagnosis of thyroid cancer is established
cytologically or histologically and molecular profiling
will effect decision regarding radioactive iodine therapy,
intensity of follow up, or for selection of targeted therapies
in patients with advanced cancer.
We will discuss the potential roles of NGS in thyroid FNA
specimens below, with an emphasis on its role in clinical
decision-making.

Potential Role of Next-Generation Sequencer in
AUS/FLUS (Bethesda Category III) Cytology
The diagnosis of AUS/FLUS should be made in FNA
specimens containing cells with architectural and/or
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nuclear atypia more pronounced than expected for benign
changes, yet not sufficient to be classified in one of the
higher risk Bethesda categories (7). Although this diagnosis
has an expected and recommended frequency of 7%,
recent analyses have found this cytological category to be
diagnosed in 1-27% of all thyroid FNA specimens (23). In
studies assessing the risk of cancer in patients with Bethesda
category III nodules, the rate of malignancy diagnosed in
patients who went to surgery was 6-48%, with a mean risk
of 16% (24).
To date only one study has assessed the performance of
ThyroSeq in AUS/FLUS (17). In this study 465 FNA samples
from 441 patients at a single institution diagnosed as AUS/
FLUS on cytology were submitted prospectively to ThyroSeq
molecular testing. In addition to the 42 gene fusions and

14 genes analyzed for point mutation, expression of eight
genes were analyzed to evaluate the cell composition of the
needle aspirates. Ninenty-eight of the cases (21%) had a
definitive diagnosis by either surgical (n=96) or non-surgical
(n=2) methods. Of all FNA samples 462 were determined
to be composed of follicular cells while three samples were
diagnosed as parathyroid in origin. Among the samples
consisting of follicular cells 31 were positive on mutational
analysis (6.7%) (Figure 1).
Of the entire group of 441 patients, 96 nodules occurring
in 90 patients were surgically removed due to the finding
of an additional nodule in the same gland with either
Bethesda V or Bethesda VI cytology in five patients.
Twenty-seven patients underwent thyroidectomy because
of positive ThyroSeq results and the remaining cases were

Figure 1. Schematic representation of study flow and overall performance of ThyroSeq in thyroid nodules with atypia of undetermined significance/
follicular lesion of undetermined significance. Results showed sensitivity 90.0% [confidence interval (CI) 78.8-100], specificity 92.1% (CI 86.0-98.2), positive
predictive value 76.9% (CI 60.7-93.1) and negative predictive value 97.2% (CI 78.8-100) with accuracy of 91.8% (CI 86.4-97.3). The overall prevalence
of a thyroid cancer diagnosis in the study of all samples of follicular cells (n=462) that underwent molecular testing was 4.8%. (Adapted from Nikiforov
YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Impact of the
multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of
undetermined significance cytology. Thyroid 2015;25:1217-1223).
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reported by the authors to have been operated on based on
patient preference. In all, 98 nodules from 92 patients had
a definitive diagnosis, either surgical (n=96) or nonsurgical.
It is important to note that the study was conducted in
a prospective manner, in that the molecular analysis
was performed prior to the surgery. Therefore, the
histopathologic diagnosis was provided by pathologists that
were not blinded to results of the NGS test. Of all FNA
samples deriving from follicular cells 31 (6.7%) were positive
for mutations (n=24) or gene fusions (n=7). The most
common genetic alteration encountered were mutations
involving RAS (n=17) and only one nodule was found to be
positive for the BRAFV600E mutation. Of the 31 nodules with
positive ThyroSeq, 26 were surgically treated while 69 out
of the total group of 431 mutation negative nodules, were
subjected to surgical removal. Of the surgeries performed,
half (n=45) were total thyroidectomies and the remaining
half underwent hemi-thyroidectomy.
Among the 26 nodules with positive ThyroSeq results that
underwent surgical treatment, 20 (77%) were ultimately
deemed to be malignant by histopathology. Eighteen
were follicular-variant papillary thyroid carcinoma and two
represented the classic variant of papillary carcinoma. Of the
six benign nodules that had tested positive for mutations,
two had NRAS mutation and the others contained single
mutations each in HRAS, E1F1AX or PTEN with one nodule
harboring a THADA fusion. On histology, 4 out of the six
benign nodules harboring mutations were classified as
follicular adenomas and the other two were deemed to
represent hyperplastic nodules.
Of the 69 thyroid nodules that were excised after testing
negative by the next generation-gene sequencer only two
were malignant on final pathology. Both tumors were
papillary carcinomas, under two centimeters in diameter,
confined to the thyroid and did not exhibit lymphovascular
invasion.
On final analysis of test performance, ThyroSeq provided
accurate classification of 91 out of 96 nodules in which
a final surgical diagnosis was available as either benign
(n=71) or malignant (n=20). Two false-negative and six
false-positive tests were encountered in the study. Based
on these findings the performance characteristics of the
test were quite favorable with a 90.9% sensitivity, 92.1%
specificity. The NPV was 97.2% and PPV 76.9%.
When interpreting the above performance characteristics
of the ThyroSeq, it is important to note that while sensitivity
and specificity are characteristics intrinsic to any test, the
resulting PPV and NPV values are highly influenced by
the pre-test probability of the disease, in other words the
performance characteristics involving predictive value will
change significantly based on the prevalence of disease in
the study population. Because the prevalence of malignancy
among AUS/FLUS that has been reported in the literature
varies between 6% and 48%, the NPV of the molecular test
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would be expected to range from 99% to 92%, and the
PPV between 42% and 91%.
Given the high sensitivity of the test for diagnosing thyroid
cancer and the resultant NPV, which is similar to that
reported for benign cytology (<5%), it has been proposed
that a negative ThyroSeq in a patient with AUS/FLUS can
generally be considered as a basis for observation rather
than surgery (17). The exception could be a population or
particular patient or nodule with a high pre-test probability
for cancer.
Though the addition of several genetic markers to the
previously reported seven-gene panel has resulted in
a decrease of PPV from 88% to 77%, the PPV for the
ThyroSeq may still be sufficient to consider it not only as a
rule-out test, but also as a rule-in test for the diagnosis of
thyroid cancer. A further strength of NGS is that the PPV is
close to 100% in the case of certain mutations including in
tumors positive for the most common BRAF mutations and
for fusions in PPARG, NTRK1, NTRK3 and ALK. One must
also take into consideration that 3 out of the 6 total “falsepositives” in this study were benign nodules harboring
RAS mutations. These are clonal neoplasms and there is
controversy that such tumors could represent pre-malignant
lesions. In fact, several lines of evidence lend support to the
hypothesis that RAS is an oncogene responsible for gradual
progression from benign to malignant thyroid lesions (25).
Though the above described findings are encouraging,
there are several limitations of the study. The study was
performed at a single institution and the participants,
including the patients, clinicians, surgeons and pathologists
were not blinded to the results of the molecular test. In fact,
the results of the test were reported to have been used as
a basis to operate in at least 27 of the cases. The unblinded
nature of the study could lead to an overestimation of
the test accuracy, a phenomenon known as review bias
or expectation bias. Given the very short-term follow-up
provided and the lack of surgical definitive diagnosis for the
large number of cases that had negative mutation analysis
and were not operated on, we cannot know for sure the
performance characteristics of the test in the entire group
of patients tested, which consists mainly of patients who
did not undergo surgery and of which none had long-term
follow-up at the time of reporting of the study findings.
Of the 462 nodules of follicular cell composition that were
submitted for molecular testing only 22 were ultimately
diagnosed as malignant. Given the lack of long term
follow up, it is reasonable to question whether some cases
of thyroid cancer remained undiagnosed among the 367
nodules that were not surgically treated.
While the authors provided data regarding the rationale
to proceed to surgery in the group of patients that were
submitted to thyroidectomy, details regarding the decisionmaking process leading to observation in the cohort not
operated on and therefore not included in the analysis of
test performance could also be of use in understanding the
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Comparison of Utility of Next-Generation
Sequencer to Other Strategies Recommended for
the Management of AUS/FLUS Cytology

full implications and the generalizability of the study results.
What were the sonographic features of the nodules in the
study? How did they correlate with results of mutation
analysis and were they used in the decision making process
to select nodules for surgery and on the extent of surgeries
performed? What were the baseline characteristics of
the patients and were other molecular tests such as GEC
also performed and utilized in the decision to observe vs.
proceed to surgery? The answers to these questions would
be helpful in understanding how the results of the study
could inform every day clinical practice.
Furthermore, while at first glance it appears to be a
strength of this study that the majority of the patients
who underwent thyroidectomy did so based on suspicious
or malignant results of a co-existing nodule other than
the nodule sampled and included in the analysis for test
performance, this also may decrease the applicability of
the test performance to the more common scenario in
which patients undergo thyroidectomy for diagnosis of
an indeterminate solitary nodule, without a co-existing
nodule with a higher risk cytological diagnosis. Thyroid
cancer, PTC in particular, is often multi-focal and patients
harboring one malignant thyroid nodule may be more likely
to have another. Whether the test would perform as well
in a large cohort of patients with solitary nodules or coexisting benign nodules is a matter that demands further
investigation.
To determine the true value of the NGS in clinical decisionmaking in this study population it would have also been
helpful to know the sonographic and other traditional
thyroid cancer risk factors of all the patients who had
ThyroSeq testing. It is possible that in a significant number
of these cases the pre-test probability of cancer may have
been high (or low) enough to justify surgery or observation
as the best management strategy, based on for instance
very high (or low) risk sonographic nodule appearance.
Also, it is possible that excluding patients who proceeded
to surgery based on the mutation analysis results or due
to “patient preference” from the calculations of test
performance characteristics would have yielded different
results.
Multi-center studies of ThyroSeq in which practitioners
and participants are blinded to test results, with long-term
follow-up including health outcomes data will provide even
more value in assessing the performance of the ThyroSeq
and its applicability and utility for “real-world” management
of thyroid nodules with Bethesda III cytology. However,
given the already recognized implications of the mutation
analysis on diagnosis as well as emerging data suggesting its
use in determining prognosis or selecting among treatment
options in some cases, it may not be considered ethical,
even at this early stage of inquiry into the role of molecular
testing in diagnosing thyroid carcinoma, to withhold results
of molecular testing from subjects enrolled in such studies.

In regards to the strategy aimed at diagnosing and
managing patients with a Bethesda category III thyroid
nodule cytology result, the 2015 ATA guidelines provide
the following recommendations (6):
“For nodules with AUS/FLUS cytology, after consideration
of worrisome clinical and sonographic features,
investigations such as repeat FNA or molecular testing may
be used to supplement malignancy risk assessment in lieu
of proceeding directly with a strategy of either surveillance
or diagnostic surgery. Informed patient preference and
feasibility should be considered in clinical decision-making
(weak recommendation, moderate-quality evidence).
If repeat FNA cytology and/or molecular testing are not
performed or inconclusive, either surveillance or diagnostic
surgical excision may be performed for an AUS/FLUS thyroid
nodule, depending on clinical risk factors, sonographic
pattern, and patient preference (strong recommendation,
Low-quality evidence).”
Prior to the availability of molecular testing for FNAs with
AUS/FLUS cytology, it was recommended to consider
repeat FNA as one approach to management (26). This was
based on the observation that approximately 50% of such
repeat FNAs resulted in benign cytology. However, a recent
report has described similar rates of malignancy in patients
undergoing surgery after benign results on repeat FNA and
those with repeatedly Bethesda category III cytology (27).
For those patients not wanting to be subjected to a repeat
FNA procedure a second-opinion review of the original FNA
specimen by a high-volume cytopathologist may result in
reclassification and could be a reasonable first-step in some
instances (28).
Ultrasound features of the nodule with AUS/FLUS cytology
may be used to aid in improving diagnostic prediction of
malignity or benignity (29,30). Retrospective studies have
reported a PPV of 60-100% when suspicious sonographic
appearance is present. However, these studies are limited
by the fact that surgical diagnosis was not available for
the majority of nodules and follow-up was short-term in
duration. The combination of sonographic characteristics
and molecular testing in AUS/FLUS has only been reported
in one study using a GEC and none using mutational
analysis or NGS (31). While this study did not show any
benefit in improving prediction provided by the molecular
testing alone, it may have not been adequately powered.
Though not commonly performed or recommended in the
evaluation of thyroid nodules, fludeoxyglucose-positron
emission tomography (FDG-PET) has been reported to have
a high NPV when applied to the diagnosis of cytologically
indeterminate thyroid nodules. In a systematic review and
meta-analysis of 6 studies FDG-PET had a low PPV (39%)
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thyroid cancer harbor a mutation in any of the 7 genes
tested.
In the largest study of molecular marker testing in FN/SFN
to date, Nikiforov and colleagues (16) reported findings of
NGS (ThyroSeq) in 143 patients with FN/SFN cytology all of
who underwent surgery for definitive diagnosis. The study
included both a cohort of 91 patients in whom the molecular
testing was performed retrospectively after surgery and
final histopathologic diagnosis, as well as a cohort of 52
consecutive FNA samples studied prospectively in which
the NGS was performed prior to thyroidectomy. While the
researchers performing the molecular testing were blinded
to the results of the surgical pathology, the pathologists
reporting on the surgical specimens were not blinded
entirely at the time of their analysis of the specimens.
The ThyroSeq included testing for 13 mutant genes as
well as 42 gene fusions known to occur in thyroid cancer.
Expression of 8 other genes was assessed to confirm the
cellular composition of the FNA sample.
Among the retrospective cohort (n=91) surgical pathology
reporting was consistent with 66 benign nodules (35
follicular adenomas and 31 hyperplastic nodules) and 25
malignant nodules (Figure 2). The malignancy rate in this
cohort was 27.5% with 3 FTC and 24 PTC, of which 19
were follicular variant PTC. The rate of malignancy was
similar in the prospective cohort at 26.9% with 38 benign
lesions and 14 malignant lesions, including 11 PTC and 3
FTC. As expected, a proportion of nodules were found to
represent Hurthle cell tumors, the frequency of which was
reported in detail for all groups.
The most frequent mutations identified were that of NRAS
(n=16) and KRAS (n=6) in which the rate of cancer diagnosed
on final histology was 81% and 83% respectively. HRAS
mutation was discovered in two samples, both of which
were malignant on final analysis. Only 1 out of 3 samples
harboring a TSH-receptor gene mutation (TSHR) was
malignant. Several other mutations, though encountered
less frequently in the cohorts, had a much higher rate of
malignancy of 100% including 4 out of 4 samples harboring
TERT mutations and one each in samples with mutations in
BRAF, TP53 and PI3K. All of the samples identified with
gene fusions (n=9), were malignant, and involved one of
the three genes PPARG, THADA and NTRK3.
Analysis of the data revealed no differences in operating
characteristics among the 2 cohorts; therefore, they were
combined to assess test performance. In the entire cohort
of 143 patients, the test performed at a 90% sensitivity
(95% confidence interval (CI), 80%-99%), 93% specificity
(95% CI, 88%-98%), an NPV of 96% (95% CI, 92%-100%),
and a PPV of 83% (95% CI, 72%-95).
Because NPV and PPV are greatly affected by prevalence
of disease in the test population, the variable rates of
malignancy for FN/SFN cytology at different institutions
would be expected to alter predictive values of any test.

and a high NPV (96%) when performed in thyroid nodules
with Bethesda category III or IV cytology (10).
While the optimal approach to the diagnosis and
management of thyroid nodules with AUS/FLUS
cytopathology remains controversial, molecular tests
including NGS have been increasingly utilized to provide
additional information to aid in the decision. In its 2015
guidelines the ATA conclude “Further research is needed to
consider the impact of considering clinical and sonographic
features on the potential utility and interpretation of
molecular testing of FNA specimens.”

Clinical Utility of Next-generation Sequencing
in Follicular Neoplasm/Suspicious for Follicular
Neoplasm (Bethesda Category IV) Cytology
According to the Bethesda system, the diagnosis of FN/
SFN should be made in thyroid aspirates that have follicular
cells arranged in an architectural pattern characterized by
cell crowding and/or microfollicle formation and lacking
nuclear features of papillary carcinoma, or are comprised
almost exclusively of oncocytic (Hurthle) cells (7). These
cytological patterns are seen with follicular and Hurthle cell
carcinomas and the follicular variant of papillary carcinoma,
however they are commonly observed in follicular
adenomas and in hyperplastic nodules as well. Since such
benign lesions are
fairly common, they have a high false-positive rate on
FN/SFN cytology, because only 14-34% of all nodules
undergoing FNA with FN/SFN cytology are identified as
malignant on the gold-standard surgical pathology (24).
In a meta-analysis of 8 studies with a total of 25,445
thyroid FNA samples, 10.1% of the results were reported
as Bethesda IV with an average 26% rate of thyroid cancer
diagnosed among these after surgery (32). The typical
management approach has been to perform diagnostic
lobectomy for such patients.
Prior to the recent introduction of ThyroSeq, available
molecular tests improved either the PPV or the NPV for FN/
SFN nodules, but not both at the same time. The GEC test,
Afirma (Veracyte, South San Francisco, California), offers
a high NPV, but its PPV is as low as 15% to 37% when
applied to FN/SFN (33,34). As a result, the GEC may not be
ideal to use as a basis to avoid diagnostic lobectomy in the
majority of patients with this cytological diagnosis when
classified as GEC suspicious, yet ultimately are found to
have benign histology. The previously reported 7-oncogene
panel yields a high PPV but a low NPV, which can aid in
selecting patients with a higher risk of cancer and may
help the surgeon decide on the appropriate extent of
surgery, but does not prevent diagnostic surgeries for the
majority of patients, in which the nodules are eventually
determined to be benign (35). The low NPV of the 7-gene
panel is due to the fact that only approximately 70% of
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IV cytopathology and negative NGS testing could be
monitored without surgery. Notable exceptions may be
in settings where the patient population has an unusually
high prevalence of thyroid cancer or in individual patients
in which the pre-test probability of cancer is exceptionally
high due to other predictive factors such as family history,
prior irradiation or high-risk sonographic characteristics
of the nodule. In those unusual clinics having a high
prevalence of thyroid cancer above 50% among their FN/
SFN patient population, indeed the NPV of ThyroSeq would
be below 90% and this could be considered too low to
avoid diagnostic lobectomy.
The 2015 ATA guideline pertaining to the management
of the patient with a thyroid nodule and FN/SFN cytology
recommends:
“A) Diagnostic surgical excision is the long-established
standard of care for the management of FN/SFN cytology
nodules. However, after consideration of clinical and

In the review of 8 studies performed by Bongiovanni
and colleagues (32), the cancer rate among Bethesda IV
varied between 14% and 34% which would result in the
ThyroSeq having a NPV between 98% and 95%, and PPV
range between 68% and 87%.
Of note, of the four false-negative results representing
thyroid malignancies without detected genetic abnormality,
all four were intra-thyroidal and none had aggressive
histopathological features. The authors speculated that the
fact that no aggressive tumors were missed could be due to
the fact that such tumors often have mutations in TERT, BRAF
or more than one mutation. Three cancers in the series were
reported to have more than one mutation. A recent case
report further underscores the possible implications of the
detection of multiple mutations and proposes a relationship
of such a finding to aggressive tumor behavior (36).
Based on the above reported data it could be concluded
that most patients with thyroid nodules with Bethesda

Figure 2. Schematic representation of study flow and overall performance of ThyroSeq in thyroid nodules with follicular neoplasm/suspicious for follicular
neoplasm. Results showed sensitivity 90% [confidence interval (CI) 80-99], specificity 93% (CI 88-98%), positive predictive value 83% (CI 72-95) and negative
predictive value 96% (CI 92-95) with accuracy of 92% (CI 88-97). (Adapted from Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding
WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Highly accurate diagnosis of cancer in thyroid nodules with follicular
neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627-3634).
FN/SFN: Follicular neoplasm/suspicious for follicular neoplasm
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sonographic features, molecular testing may be used
to supplement malignancy risk assessment data, in lieu
of proceeding directly with surgery. Informed patient
preference and feasibility should be considered in clinical
decision-making (weak recommendation, moderate-quality
evidence).
B) If molecular testing is either not performed or
inconclusive, surgical excision may be considered for
removal and definitive diagnosis of an FN/SFN thyroid
nodule (strong recommendation, low-quality evidence)”.

Mol Imaging Radionucl Ther 2017;26(Suppl 1):24-35

nodules, were written at a time when total or near-total
thyroidectomy was recommended as the initial surgical
procedure for most cases of thyroid cancer, the current
guidelines suggest more conservative surgical management
(i.e., hemi-thyroidectomy) be considered as an option for
low-risk thyroid cancer (38). This change could affect the
utility of the result of NGS to determine extent of surgery
for patients with indeterminate cytology and positive
mutational analysis. Furthermore, there are no long-term
outcome data testing the strategy of using NGS or other
molecular tests in indeterminate FNA specimens to stratify
surgical approach.
In summary the 2015 guidelines of the ATA provide the
following recommendation: “If molecular testing is being
considered, patients should be counseled regarding the
potential benefits and limitations of testing, and about
the possible uncertainties in the therapeutic and long-term
clinical implications of results”.

Recommendations on the Use of Next-generation
Sequencing from Clinical Practice Guidelines
In 2015 the ATA published revised guidelines on the
management of adult patients with thyroid nodules and
thyroid cancer (6). These guidelines included a thoughtful
and detailed discussion of the potential role of molecular
testing in the diagnosis of thyroid nodules and their
implications for the management of patients with thyroid
nodules and cancer. It should be noted that though the
guideline included discussion of the previously reported 7
gene mutational analysis panel and the published reports of
ThyroSeq in FN/SFN cytology, the more recent publication
regarding performance of ThyroSeq in AUS/FLUS was
not available at the time of publication of the 2015 ATA
guidelines.
The authors of the ATA guidelines created a framework
for the use of molecular testing including a classification
of such tests according to intended use as either for
diagnostic purposes (for classification of a disease state),
prognostic or predictive purposes (to provide predictive
information regarding the probability of benefit or harm of
a specific treatment) (37). The ATA authors emphasize that
since there is a lack of long-term outcomes data regarding
the use of molecular testing to guide therapeutic decisionmaking, it remains unknown whether routine use of such
tests in clinical practice would result in a net benefit in the
health of patients with thyroid nodules and thyroid cancer.
Similarly, a National Comprehensive Cancer Network task
force report has declared that the clinical utility of any
molecular test must be based on strong evidence that
use of the test “improves patient outcomes sufficiently to
justify its incorporation into routine clinical practice” (37).
Taking into account the above principles, the ATA guidelines
recommend that the current use of molecular marker testing
for patients with indeterminate thyroid nodule cytology is
primarily diagnostic (to rule in or rule out malignancy), with
an added implication of a companion use to aid in decisionmaking on initial surgical management (the decision to
perform surgery and to guide the extent of surgery).
The 2015 ATA guidelines also point out that while previously
published guidelines, including the ATA statement on
surgical application of molecular profiling of thyroid

Potential Use of Mutational Analysis for
Prognostication and Targeted Therapy of Thyroid
Cancer
A strength of NGS when applied as a diagnostic test
to patients with thyroid nodules and thyroid cancers is
the potential impact that knowledge of the underlying
genetic anomaly could have on prognostication and
implications for treatment decisions. Mutations involving
AKT1, TP53, PIK3CA and CTNNB1 are rarely present in
benign thyroid nodules and common in more advanced
thyroid cancers (39). TERT mutations in particular have
been associated with increased disease specific mortality,
distant metastasis and radioactive iodine refractory
disease (40,41,42). BRAFV600E mutations are associated
with higher recurrence rates and mortality in thyroid
cancer (43). However, it remains controversial whether
mutational status provides further prognostic information
to that already provided by more traditional prognostic
factors such as patient characteristics and grade and
stage of disease at presentation. For thyroid papillary
microcarcinoma evidence suggested that BRAF status
together with several histopathologic features was a
better predictor of extrathyroid tumor spread than either
mutation or histopathologic findings alone (44).
It is likely that with increasing application of mutational
analysis in thyroid nodules and cancers, and analysis of
prospective studies of its use will provide data to answer
this question in the future.
It must also be taken into consideration that while factors
inherent to the tumor, including mutation status, have effects
on prognosis; “host factors” involving the patient harboring
the tumor may independently, or via complex interactions
with the genomic alterations of the tumor have effects on
tumor behavior and prognosis. Underscoring this point is a
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NPV and an improved PPV when compared to existing
molecular tests. Large-scale multi-center studies are needed
to validate these preliminary findings. Furthermore, future
studies are needed to determine the optimal use of NGS
in clinical-decision making for patients with indeterminate
cytopathology after thyroid FNA. Several studies and reports
point to the potential impact that knowledge of mutational
status of thyroid tumors can have on prognostication and
selection of targeted-therapies, though it remains to be
elucidated whether strategies to treat thyroid cancer based
on mutational status will improve overall outcomes. As
we look ahead to the era of “personalized medicine” NGS
appears to hold promise as a potentially useful tool in the
detection of thyroid malignancy as well as a possible aid for
the clinician in determining optimal treatment for patients
with thyroid neoplasia.

recent report associating obesity with increased prevalence
of BRAFV600E mutations among patients with PTC (45).
Targeted therapies directed by results of mutational
analysis are recommended for a variety of cancers.
Treatment of melanoma based on BRAF status and
assessment of KRAS mutational status to determine
medical treatment for colorectal cancer are strategies
that have been tested in clinical trials (46,47). While
targeted therapy based on mutational analysis is not
yet a widely accepted practice for thyroid cancer
there are several clinical trials in progress to test this
hypothesis. Clinical trials of MEK or BRAF inhibitors to
increase radioiodine uptake for patients with BRAFmutant, RAI-refractory thyroid carcinoma (ClinicalTrials.
gov Identifier: NCT02145143) and RAS mutated thyroid
cancer (ClinicalTrials.gov Identifier: NCT02152995)
are underway. Studies of combination of BRAF
and MEK inhibitors for patients with BRAF mutant
anaplastic thyroid cancer (ClinicalTrials.gov Identifier:
NCT02034110) are also enrolling patients. Patients with
advanced thyroid cancers harboring PAX8/PPARγ fusions
(ClinicalTrials.gov Identifier: NCT01655719) and NTRK
alterations (ClinicalTrials.gov Identifier: NCT02122913)
are now being treated in clinical trials. Previous data
showed that STRN-ALK fusions occur more often with
aggressive types of thyroid cancer and several reports
have demonstrated that patients with advanced thyroid
cancer with ALK fusions may benefit from ALK inhibitors
such as Crizotinib (48). Not previously seen in thyroid
cancer, a mutation in the TSC2 and in the mTOR protein
was discovered in a patient with metastatic anaplastic
thyroid cancer who initially achieved a near-complete
response to Everolimus with posterior resistance and
progression of the disease. This shows the possible
benefit of sequencing a patient’s cancer DNA prior to
treatment and following disease recurrence, which may
help guide treatment in patients with similar mutations
(49).
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